Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 1.00 |
| ▸ | CA12 | O43570 | 4/20 | 1.00 |
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | CA9 | Q16790 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718969 | 1.00 | CA1 (1.00) | CA1CA12CA2CA9KMT2A | |
| Hydrochloric Acid SCHEMBL28023173 | 0.98 | CA1 (0.96) | CA1CA12CA2CA9KMT2A | |
| SCHEMBL6496816 | 0.73 | CA1 (0.58) | CA1CA12CA2CA9LMNA | |
| SCHEMBL2776254 | 0.73 | CA1 (0.58) | CA1CA12CA2CA9LMNA | |
| SCHEMBL28961017 | 0.73 | CA1 (0.58) | CA1CA12CA2CA9KMT2A | |
| SCHEMBL2777400 | 0.73 | CA1 (0.58) | CA1CA12CA2CA9LMNA | |
| SCHEMBL6494977 | 0.73 | CA1 (0.58) | CA1CA12CA2CA9KMT2A | |
| SCHEMBL6505477 | 0.73 | CA1 (0.58) | CA1CA12CA2CA9LMNA | |
| SCHEMBL30070404 | 0.73 | CA1 (0.58) | CA1CA12CA2CA9KMT2A | |
| SCHEMBL10082924 | 0.73 | CA1 (0.58) | CA1CA12CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113773277-B | Synthesis method of 4H-1,2, 4-benzothiadiazine-1, 1-dioxide derivative | 兰州大学 | 2023-12-05 | — | — | CN | claimed |
| CN-117285484-B | Benzothiadiazine 1, 1-dioxide compounds inhibiting HDAC6 enzyme, preparation method and application thereof | Shanghai Pharmaceutical Industry Research Institute Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| WO-2025076455-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | Escient Pharmaceuticals Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119504808-A | Compound, preparation method and application thereof | 四川科伦药物研究院有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-06-20 | — | — | US | disclosed |
| CN-117946012-A | Preparation method of nitrogen-containing heterocycle | 温州理工学院 | 2024-04-30 | — | — | CN | disclosed |
| CN-117285484-A | Benzothiadiazine 1, 1-dioxide compounds inhibiting HDAC6 enzyme, preparation method and application thereof | 上海医药工业研究院有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-113773277-B | Synthesis method of 4H-1,2, 4-benzothiadiazine-1, 1-dioxide derivative | 兰州大学 | 2023-12-05 | — | — | CN | disclosed |
| CN-113773277-B | Synthesis method of 4H-1,2, 4-benzothiadiazine-1, 1-dioxide derivative | 兰州大学 | 2023-12-05 | — | — | CN | disclosed |
| CN-113773277-B | Synthesis method of 4H-1,2, 4-benzothiadiazine-1, 1-dioxide derivative | 兰州大学 | 2023-12-05 | — | — | CN | disclosed |
| CN-111410638-B | Benzothiadiazine methoxyl acrylate derivatives, and preparation method and application thereof | 天津农学院 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | CA1 1382/4885CA12 1492/4885CA2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.